title: [STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome].
abstract: Functional gastro-intestinal diseases such as functional dyspepsia and irritable bowel syndrome are a therapeutic challenge, as they are not only characterized by a multitude of symptoms, some of them with severe consequences for affected patients, but are also caused by a multitude of factors. The clinical efficacy of the therapeutics STW 5/Iberogast in these diseases has been proven in a number of randomized prospective clinical studies. Several preclinical studies suggest that its efficacy could be due to its complex composition of nine standardized herbal extracts, which act differently on multiple sites. This principle, which is quite popular in clinical medicine, was introduced as a multi-target therapy for functional bowel disorders. Components of STW 5/Iberogast reduce gastro-intestinal hypersensitivity and act spasmolytic on spastic, tonicising on atonic gastro-intestinal muscle. In addition a stimulating effect on reduced mucus-secretion, an inhibitory effect on enhanced gastric acid secretion and an anti-inflammatory effect have been shown. These effects could explain the clinical efficacy of STW5/Iberogast in a large range of symptoms.
authors: Zentrum für Innere Medizin, Gastroenterologie, Hepatologie und Metabolismus, Klinikum Garmisch-Partenkirchen, Akademisches Lehrkrankenhaus der Ludwig-Maximilians-Universität München, Garmisch-Partenkirchen, Germany. hans.allescher@klinikum-gap.de
authors: Hans-Dieter
authors: HD
authors: Allescher
authors: Hildebert
authors: H
authors: Wagner
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy*; D006168:Guinea Pigs; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D015201:Meta-Analysis as Topic; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D051381:Rats
chemical_list: D010936:Plant Extracts; C039964:iberogast
references: Curr Treat Options Gastroenterol. 2004 Aug;7(4):265-272
references: 15238201
references: Arzneimittelforschung. 2001;51(7):545-53
references: 11505785
references: Phytomedicine. 2006;13 Suppl 5:122-9
references: 16772111
references: Phytomedicine. 2006;13 Suppl 5:12-9
references: 16857355
references: Aliment Pharmacol Ther. 2004 Dec;20(11-12):1279-87
references: 15606389
references: Digestion. 2004;70(4):257-64
references: 15687728
references: Z Gastroenterol. 2001 Jul;39(7):511-7
references: 11505331
references: Scand J Gastroenterol. 2002 May;37(5):617-8; author reply 618-20
references: 12059067
references: Neurogastroenterol Motil. 2004 Dec;16(6):759-64
references: 15601426
references: Forsch Komplementarmed Klass Naturheilkd. 2002 Dec;9 Suppl 1:1-20
references: 12618546
references: Phytomedicine. 2006;13 Suppl 5:51-5
references: 16973340
references: Phytomedicine. 2006;13 Suppl 5:90-9
references: 16765572
references: Neurogastroenterol Motil. 2004 Dec;16(6):765-73
references: 15601427
references: Phytomedicine. 2006;13 Suppl 5:67-74
references: 16978852
references: Phytomedicine. 2006;13 Suppl 5:45-50
references: 16713223
references: Phytomedicine. 2006;13 Suppl 5:56-66
references: 16963243
references: Am J Gastroenterol. 2007 Jun;102(6):1276-83
references: 17378904
references: Wien Med Wochenschr. 2004 Nov;154(21-22):528-34
references: 15638072
references: Phytomedicine. 2006;13 Suppl 5:2-11
references: 16859904
references: Adv Ther. 2003 Jan-Feb;20(1):43-9
references: 12772817
references: Phytomedicine. 2006;13 Suppl 5:36-44
references: 16777393
references: Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9
references: 14984373
references: Z Gastroenterol. 2002 Jun;40(6):401-8
references: 12055663
references: Phytomedicine. 2006;13 Suppl 5:75-9
references: 16709451
references: Phytomedicine. 2006;13 Suppl 5:114-21
references: 16978851